[go: up one dir, main page]

PE20081458A1 - DERIVADOS DE PIRIDO[2,3-b]INDOL COMO INHIBIDORES DE QUINASAS - Google Patents

DERIVADOS DE PIRIDO[2,3-b]INDOL COMO INHIBIDORES DE QUINASAS

Info

Publication number
PE20081458A1
PE20081458A1 PE2007001361A PE2007001361A PE20081458A1 PE 20081458 A1 PE20081458 A1 PE 20081458A1 PE 2007001361 A PE2007001361 A PE 2007001361A PE 2007001361 A PE2007001361 A PE 2007001361A PE 20081458 A1 PE20081458 A1 PE 20081458A1
Authority
PE
Peru
Prior art keywords
pyrid
halo
alkyl
indol
alcoxy
Prior art date
Application number
PE2007001361A
Other languages
English (en)
Inventor
Janson W Brown
Qing Dong
Bheema R Paraselli
Jeffrey A Stafford
Michael B Wallace
Original Assignee
Takeda San Diego Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40754069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081458(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2006/039667 external-priority patent/WO2007044779A1/en
Application filed by Takeda San Diego Inc filed Critical Takeda San Diego Inc
Publication of PE20081458A1 publication Critical patent/PE20081458A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)

Abstract

SE REFIERE A DERIVADOS DE PIRIDO[2,3-b]INDOL DE FORMULA (I), EN DONDE R2 ES -Y2-R13; Y2 ESTA AUSENTE O ES UNA SEPARACION DE 1 O 2 ATOMOS SELECCIONADOS DE O, N U S; R4 ES H, HALO, NITRO, CIANO, TIO, OXI, HIDROXI, CARBONILOXI, ALCOXI, AMINO, ENTRE OTROS; R5 Y R6 SON INDEPENDIENTEMENTE H, HALO, TIO, OXI, HIDROXI, ARILOXI, ALCOXI, ENTRE OTROS; R7ES H, HALO, HIDROXI, ALCOXI, AMINO Y ALQUILO(C1-C5); R12 Y R13 SON INDEPENDIENTEMENTE H, HALO, NITRO, CN, ENTRE OTROS; R16 ES AMINO, ALQUIL(C1-C10)AMINO, ALQUILO(C1-C10), ENTRE OTROS; R23 ES H, CARBONILO, ALQUILO(C1-C10), HALOALQUILO(C1-C10), CARBONILALQUILO(C1-C3), ENTRE OTROS. SON SELECCIONADOS N-(2-METILAMINO)ETIL-5-(3-(ETILSULFONIL)FENIL)-3,8-DIMETIL-9H-PIRIDO[2,3-b]INDOL-7-CARBOXAMIDA, (5-(3-(ETILSULFONIL)FENIL)-3,8-DIMETIL-9H-PIRIDO[2,3-b]INDOL-7-IL)(MORFOLINO)METANONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN CONJUNTO DE ELEMENTOS O KIT. ESTOS COMPUESTOS SON INHIBIDORES DE QUINASAS EN ESPECIAL DE LA AURORA B-QUINASA, SIENDO UTILES EN EL TRATAMIENTO DEL CANCER SELECCIONADO DE CARCINOMA DE CELULAS ESCAMOSAS, ASTROCITOMA, SARCOMA DE KAPOSI, GIOBASTOMA, ENTRE OTROS
PE2007001361A 2006-10-10 2007-10-10 DERIVADOS DE PIRIDO[2,3-b]INDOL COMO INHIBIDORES DE QUINASAS PE20081458A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2006/039667 WO2007044779A1 (en) 2005-10-07 2006-10-10 Kinase inhibitors
US91262507P 2007-04-18 2007-04-18

Publications (1)

Publication Number Publication Date
PE20081458A1 true PE20081458A1 (es) 2008-12-03

Family

ID=40754069

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001361A PE20081458A1 (es) 2006-10-10 2007-10-10 DERIVADOS DE PIRIDO[2,3-b]INDOL COMO INHIBIDORES DE QUINASAS

Country Status (7)

Country Link
US (2) US20090156557A1 (es)
EP (1) EP2223925A1 (es)
JP (1) JP2010505961A (es)
AR (1) AR063232A1 (es)
CL (1) CL2007002919A1 (es)
PE (1) PE20081458A1 (es)
TW (1) TW200823212A (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
BRPI0719883A2 (pt) * 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
WO2009129259A2 (en) * 2008-04-16 2009-10-22 Takeda Pharmaceutical Company Limited Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
JP2014169273A (ja) * 2013-02-06 2014-09-18 Tosoh Organic Chemical Co Ltd 環式芳香族化合物の製造方法
WO2016044463A2 (en) 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
PL3640251T3 (pl) 2016-10-24 2022-04-11 Astrazeneca Ab Pochodne 6,7,8,9-tetrahydro-3H-pirazolo[4,3-f]izochinoliny przydatne w leczeniu nowotworu złośliwego
MY196317A (en) 2017-01-30 2023-03-24 Astrazeneca Ab Estrogen Receptor Modulators
MX387359B (es) * 2017-03-16 2025-03-18 Bristol Myers Squibb Co Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
US11230551B2 (en) * 2017-03-16 2022-01-25 Celgene Car Llc Deuterated analogs of MK2 inhibitors and uses thereof
WO2021214253A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Dosage regimen for the treatment of cancer
IL297218A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Pharmaceutical formulations
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
GB2013703B (en) * 1978-01-25 1982-06-03 Bayer Ag Heterocyclic dyestuffs
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
US6759212B1 (en) * 1997-08-15 2004-07-06 Chugai Seiyaku Kabushiki Kaisha Cell cycle-regulating proteins
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6706491B1 (en) * 1999-04-09 2004-03-16 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by p21
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
HK1050191B (en) * 1999-12-24 2011-04-29 Aventis Pharma Limited Azaindoles
EP1294709A2 (en) * 2000-01-28 2003-03-26 AstraZeneca AB Quinoline derivatives and their use as aurora 2 kinase inhibitors
CA2369076A1 (en) * 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
CN1362953A (zh) * 2000-02-05 2002-08-07 沃泰克斯药物股份有限公司 用作erk抑制剂的吡唑组合物
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6555329B2 (en) * 2000-06-09 2003-04-29 Boehringer Ingelheim International Gmbh Method for identifying compounds altering higher-order chromatin-dependent chromosome stability
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US6352858B1 (en) * 2000-09-11 2002-03-05 Isis Pharmaceuticals, Inc. Antisense modulation of BTAK expression
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1317450B1 (en) * 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
US6659911B2 (en) * 2000-11-28 2003-12-09 Yamaha Marine Kabushiki Kaisha Shift assist system for an outboard motor
CA2432417A1 (fr) * 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
CA2432222C (en) * 2000-12-21 2008-07-29 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
EP1390141B1 (en) * 2001-04-28 2010-06-23 China Petroleum & Chemical Corporation A rare earth zeolite y and the preparation process thereof
HRP20030910B1 (hr) * 2001-05-14 2011-11-30 Pfizer Products Inc. Tartaratne soli 5,8,14-triazatetraciklo {10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>}-heksadeka-2(11), 3,5,7,9-pentaena i pripadajućih farmaceutskih spojeva
CA2448076A1 (en) * 2001-05-24 2002-11-28 Masahiko Hayakawa 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
MXPA03010961A (es) * 2001-05-31 2004-02-27 Vertex Pharma Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
ATE339418T1 (de) * 2001-06-01 2006-10-15 Vertex Pharma Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003012046A2 (en) * 2001-07-27 2003-02-13 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
WO2003011287A1 (en) * 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Pyrazolon derivatives as inhibitors of gsk-3
CA2455631A1 (en) * 2001-08-06 2003-02-20 Pharmacia Italia S.P.A. Aminoisoxazole derivatives active as kinase inhibitors
US20030073692A1 (en) * 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
US6806272B2 (en) * 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
ATE363473T1 (de) * 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
AU2002341729A1 (en) * 2001-09-19 2003-04-01 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
US20030109550A1 (en) * 2001-09-19 2003-06-12 Michael Clare Substituted indazole compounds for the treatment of inflammation
CN1316634C (zh) * 2001-10-03 2007-05-16 株式会社东芝 X光平面检测器
US20040010027A1 (en) * 2001-12-17 2004-01-15 Pharmacia & Upjohn Spa Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them
MXPA04006260A (es) * 2001-12-24 2005-03-31 Astrazeneca Ab Derivados de quinazolina sustituidos como inhibidores de cinasas aurora.
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US7179826B2 (en) * 2002-03-15 2007-02-20 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
EP1485376B1 (en) * 2002-03-15 2007-06-27 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20040009981A1 (en) * 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
WO2003077921A1 (en) * 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azinylaminoazoles as inhibitors of protein kinases
AU2003237121A1 (en) * 2002-04-26 2003-11-10 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
US6989451B2 (en) * 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CA2491895C (en) * 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
RU2005106871A (ru) * 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение
KR20050057520A (ko) * 2002-09-23 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 이미다조피라진
AU2003295584A1 (en) * 2002-11-18 2004-06-15 Taurus Hsa Llc Method for continuous, automated blending of solutions from acids and bases
ATE440087T1 (de) * 2003-01-30 2009-09-15 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
ATE482200T1 (de) * 2003-05-01 2010-10-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
US20050125852A1 (en) * 2003-05-09 2005-06-09 Sugen, Inc. Novel kinases
KR20060069356A (ko) * 2003-06-20 2006-06-21 카이론 코포레이션 항암제로서 피리디노[1,2-α]피리미딘-4-온 화합물
US20050065171A1 (en) * 2003-06-25 2005-03-24 Shakespeare William C. Substituted purine derivatives
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7141568B2 (en) * 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20050026984A1 (en) * 2003-07-29 2005-02-03 Aventis Pharma S.A. Substituted thieno [2,3-c] pyrazoles and their use as medicinal products
US7094791B2 (en) * 2003-07-31 2006-08-22 Avalon Pharmaceuticals, Inc. Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof
US7279575B2 (en) * 2003-08-08 2007-10-09 Pfizer Italia S.R.L. Pyrimidylpyrrole derivatives active as kinase inhibitors
US20050043346A1 (en) * 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
US7157476B2 (en) * 2003-08-20 2007-01-02 Vertex Pharmaceuticals Incorporated Aminofurazan compounds useful as protein kinase inhibitors
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
CA2546360A1 (en) * 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc Methods of treating diseases and disorders by targeting multiple kinases
FR2865934B1 (fr) * 2004-02-05 2006-05-05 Sanofi Synthelabo Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
PE20051128A1 (es) * 2004-02-25 2006-01-16 Schering Corp Pirazolotriazinas como inhibidores de quinasa
FR2868421B1 (fr) * 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
FR2871158A1 (fr) * 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004034623A1 (de) * 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
WO2006021547A1 (de) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinone als plk (polo like kinase) inhibitoren
EP1784406A1 (de) * 2004-08-27 2007-05-16 Boehringer Ingelheim International GmbH Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
FR2876377B1 (fr) * 2004-10-11 2007-03-16 Univ Claude Bernard Lyon Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
CA2581516C (en) * 2004-10-12 2013-06-11 Astrazeneca Ab Quinazoline derivatives
FR2882751B1 (fr) * 2005-03-04 2007-09-14 Aventis Pharma Sa Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, procede de preparation, compositions les contenant et utilisation
FR2884821B1 (fr) * 2005-04-26 2007-07-06 Aventis Pharma Sa Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
WO2006131552A1 (de) * 2005-06-09 2006-12-14 Boehringer Ingelheim International Gmbh Alpha-carboline als cdk-1 inhibitoren
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2145878A3 (en) * 2006-10-09 2010-02-24 Takeda Pharmaceutical Company Limited Aurora Kinase inhibitors
WO2009129401A1 (en) * 2008-04-16 2009-10-22 Takeda Pharmaceutical Company Limited Kinase inhibitors

Also Published As

Publication number Publication date
US20090156557A1 (en) 2009-06-18
TW200823212A (en) 2008-06-01
EP2223925A1 (en) 2010-09-01
CL2007002919A1 (es) 2008-03-14
JP2010505961A (ja) 2010-02-25
AR063232A1 (es) 2009-01-14
US20100160633A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
PE20081458A1 (es) DERIVADOS DE PIRIDO[2,3-b]INDOL COMO INHIBIDORES DE QUINASAS
DE602005023343D1 (de) Pyrimidinderivate als gpcr-agonisten
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
PE20090287A1 (es) Derivados de piridazinona
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
ES2422299T3 (es) Indoles (4,5-dihidro) indoles tricíclicos
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20091371A1 (es) Inhibidores de hsp90
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
PE20110397A1 (es) Compuestos que modulan selectivamente el receptor cb2
PE20121358A1 (es) Derivados de indol como inhibidores itk
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20081316A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
DK1912979T3 (da) Phenyl-{3-{3-(1H-pyrrol-2-YL)-[1,2,4]oxadiazol-5-YL]piperidin-1-YL}-methanon-derivater og beslægtede forbindelser som positive allosteriske modulatorer af metabotrope glutamat-receptorer
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
TW200745117A (en) Macrocylic inhibitors of hepatitis C virus
MX2009010909A (es) Derivados de ftalazino y su uso como medicamento para tratar el cancer.
PE20090372A1 (es) Derivados de indolinonas como inhibidores de quinasas especificas del ciclo celular
PE20071031A1 (es) Derivados de tiadiazolidinona como inhibidores de ptpasas
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal